130 related articles for article (PubMed ID: 33858423)
1. Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma.
Meng Y; Qian X; Zhao L; Li N; Wu S; Chen B; Sun T; Wang X
Cancer Cell Int; 2021 Apr; 21(1):216. PubMed ID: 33858423
[TBL] [Abstract][Full Text] [Related]
2. Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.
Liu Y; Xiong ZC; Sun X; Sun L; Zhang SL; Ma JT; Han CB
Transl Cancer Res; 2019 Sep; 8(5):2151-2163. PubMed ID: 35116965
[TBL] [Abstract][Full Text] [Related]
3. Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.
Huang G; Liu X; Jiang T; Cao Y; Sang M; Song X; Zhou B; Qu H; Cai H; Xing D; Mao Y; Lin G; Liu X; Zheng X
Am J Cancer Res; 2023; 13(9):4145-4162. PubMed ID: 37818074
[TBL] [Abstract][Full Text] [Related]
4. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple
Zheng Q; Chen D; Wang X; Yang Y; Zhao S; Dong X; Ma C; Zhang X; Duan H; Sun Y; Zheng S
Ann Transl Med; 2022 Jun; 10(12):696. PubMed ID: 35845484
[TBL] [Abstract][Full Text] [Related]
5. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
8. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
9. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.
La Monica S; Fumarola C; Cretella D; Bonelli M; Minari R; Cavazzoni A; Digiacomo G; Galetti M; Volta F; Mancini M; Petronini PG; Tiseo M; Alfieri R
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374971
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
12. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
14. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
15. The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.
Dai X; Liu X; Ge F; Zhu H; Zheng C; Yan F; Yang B
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):558-566. PubMed ID: 37899396
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
17. DUSP1 Promotes Osimertinib Drug-Tolerant Persistence by Inhibiting MAPK/ERK Signaling in Non-small Cell Lung Cancer.
He W; Liu P; Lei Q; Xu J; Liu L
Mol Biotechnol; 2024 Mar; ():. PubMed ID: 38551790
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
19. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated expression of microRNA involved in resistance to osimertinib in
Zhang D; Yang Y; Kang Y; Xie D; Zhang X; Hao J
J Thorac Dis; 2023 Apr; 15(4):1978-1993. PubMed ID: 37197540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
